CAS: 10212-25-6; (2R,3R,3As,9Ar)-2-(Hydroxymethyl)-6-Imino-3,3A,6,9A-Tetrahydro-2H-Furo[2',3':4,5]Oxazolo[3,2-A]Pyrimidin-3-Ol Hydrochloride

相似化合物

10212-25-6 31698-14-3 60046-80-2

上下游产品

CAS号3083-77-0 阿糖尿苷 | CAS号34079-68-0 2-氨基阿糖腺苷 | CAS号147-94-4 阿糖胞苷

胞苷置于碳酸乙烯酯体系中,用 N,N-二甲基甲酰胺 用作溶剂,化学反应 2.0H,以47.7%的收率获得盐酸环胞苷
参考文献:一种盐酸阿糖胞苷的制备方法
标题:一种盐酸阿糖胞苷的制备方法
摘要:本发明提供了一种盐酸阿糖胞苷的制备方法,包括以下步骤:A)胞苷和乙酰水杨酰氯进行酰化反应,得到乙酰环胞苷;B)乙酰环胞苷在盐酸甲醇溶液中进行脱保护,得到盐酸环胞苷;C)盐酸环胞苷进行开环得到盐酸阿糖胞苷.本发明提供的盐酸阿糖胞苷的制备方法,不仅原料廉价易得,而且避开了使用高毒,难去除物质,不仅安全环保,而且得到的产品收率和纯度均较高.

专利信息

专利号:US-3856777-A
优先权日:1971-12-14
标题:Method of producing pyrimidine nucleoside derivatives
发明人：ISHIDO Y; YOSHINO T; YAMASAKI A; OKUTSU M; KOMURA H; SUZUKI K
权利人:AJINOMOTO KK
摘要:Uridine, cytidine, and derivatives thereof arrived at by substitution in positions 4, 5 and 5'' are converted to the corresponding 2,2''-anhydro compounds by reaction with cyclic lower alkylene and alkenylene esters of carbonic acid. The anhydro compounds are hydrolyzed to arabinofuranosylpyrimidine derivatives in a basically known manner. The latter as well as the anhydro compounds are known physiologically active agents and/or intermediates in the synthesis of such agents.

专利号:US-3978042-A
优先权日:1975-01-31
标题 :Process for preparing cyclocytidine derivatives
发明人：HESSLER EDWARD J
权利人:UPJOHN CO
摘要:A new method for preparing cytosine arabinoside involving the cyanovinylation of the aminooxazoline of D-arabinose by cis-β-[trimethylammonium]-acrylonitrile tosylate. Also included are new preparations of the aminooxazoline of D-arabinose and the anion of cis-1-cyano-2-hydroxyethylene. n DESCRIPTION OF THE PRIOR ART n Cytosine arabinoside, an anti-leukemic agent also known as 1-β-D-arabinofuranosylcytosine, is a known anti-leukemic agent. Consequently, an economical and safe synthesis of the compound and other significant cytosine nucleosides is an important contribution to the well being of the populace. The Orgel and Sanchez patent, U.S. Pat. No. 3,658,788, provided a new way of preparing cytosine nucleosides, particularly cytosine arabinoside. The process consisted of preparing an aminooxazoline intermediate which is then cyanovinylated to a cyclocytidine salt. The cyclocytidine salt is then treated with aqueous ammonia to form the cytosine nucleoside. However, difficulties accompany these synthetic pathways. In the cyanovinylation step, many of the electrophilic reagents were too costly to use in a commercially oriented process. Those reagents that were commercially feasible, cost-wise, suffered from other serious defects. Cyanoacetylene, for example, is extremely hazardous because of its tendency to explode. n A new process for preparing cytosine arabinoside has been discovered. Although the synthesis goes through the aminooxazoline intermediate, a separate isolation step of this intermediate is not required. Furthermore, a new cyanovinylating agent without the serious problems of the past agents has now been discovered. The invention also includes new methods for preparing the aminooxazoline and the cyanovinylating agent. n BRIEF SUMMARY OF THE INVENTION n A process for preparing cyclocytidine tosylate salt has been discovered which comprises: n A. reacting D-arabinose with cyanamide or cyanide plus aqueous ammonia in an inert solvent to prepare the aminooxazoline of D-arabinose n B. contacting the said aminooxazoline of Step a with cis-β- [trimethylammonium]-acrylonitrile tosylate. n A further aspect of the invention is the preparation of the aminooxazoline of D-arabinose which comprises reacting D-arabinose with cyanamide in an inert, aprotic solvent in an essentially dry environment with catalytic quantities of a base present. n A still further aspect of this invention is the preparation of the compound ##SPC1## n Which comprises reacting the aminooxazoline of D-arabinose with cis-β-[trimethylammonium]-acrylonitrile tosylate. n Another aspect of this invention is the selective preparation of the anion of cis-1-cyano-2-hydroxyethylene which comprises contacting isoxazole with a base of a strength equal to or greater than sodium methoxide which is in an inert organic solvent at a temperature less than or equal to -40°C. It has also been found that the temperature of the isoxazole at the time of the addition is critical. If isoxazole is at an ambient temperature, the -40°C. is essential for proper yields of the cis anion. However, if the isozazole is cooled prior to addition, the reaction solution may be maintained at a higher temperature. n A further aspect of the invention is the compound cis-β-[trimethylammonium]-acrylonitrile tosylate. n DETAILED DESCRIPTION OF THE INVENTION n A similar pathway to cytosine arabinoside, through the aminooxazoline intermediate, is illustrated in the aforementioned Orgel and Sanchez patent. With regard to preparing the aminooxazoline of cytosine arabinoside, the disclosure of Orgel and Sanchez appearing at Column 4, line 63 to Column 6, line 11, is herein incorporated by reference. A new, more preferred method of preparing the aminooxazoline has been discovered. This method comprises reacting D-arabinose with cyanamide in an inert, aprotic solvent in an essentially dry environment with catalytic quantities of a base present to form the aminooxazoline of D-arabinose. Rather than working in an aqueous system, an essentially dry system is preferred. Consequently, cyanamide is preferred over the usually aqueous system of ammonia and cyanogen. Cyanamide can be obtained commercially as solid calcium cyanamide or as an aqueous solution of cyanamide. However, the calcium cyanamide can be converted to free cyanamide by the addition of hydrochloric acid followed by extractive purification. Anhydrous cyanamide can be additionally prepared by contacting aqueous cyanamide with calcium chloride followed by ethyl acetate extraction of cyanamide. n The solvent employed in this reaction is preferably an inert aprotic, organic solvent such as dialkylamides and dialkylsulfoxides which are liquid at the reaction temperature. Examples of such solvents include dimethylformamide, dimethylacetamide, dimethylsulfoxide, diethylformamide, diethylacetamide and the like. n For improved reaction yields of oxazoline and length of time of reaction, a catalytic quantity of base is preferred. Bases which can be employed are carbonates of metals such as potassium, lithium, and sodium; bicarbonates such as potassium, lithium and sodium; and ammonia. Organic bases such as pyridine, lutidine and triethylamine can also be used. The most preferred base is potassium bicarbonate. When using a solid material such as potassium bicarbonate, it is found to be preferable that it is micronized. A dry, free flowing material appears to provide better yields. n The quantity of catalyst employed is from about 10-30 g./150 g. of D-arabinose when using a solid catalyst. If a liquid catalyst is employed, the quantity of catalyst is from about 0.1 to 1.0 mole equivalent of D-arabinose. n The reaction can be conveniently carried out at a temperature of from about 30° to about 130°C. The lower end of the temperature range is somewhat dependent upon the reaction time. Oxazoline will be formed, but at a lower rate. The upper end of the temperature range is dependent upon the yield of oxazoline one desires. For example, as the temperature increases, oxazoline degrades more readily. n The reaction time is dependent upon the temperature. However, it has been found that a reaction time of 75 minutes at a temperature of 90°C. brings about a good yield of oxazoline in a reasonable length of time. n The oxazoline is now converted to the cyclocytidine salt by reaction with the cyanovinylating agent, cis-β-[trimethylammonium]-acrylonitrile tosylate. The oxazoline can be reacted directly with the acrylonitrile without isolation from its reaction vessel, if desired. Otherwise the oxazoline can be isolated by standard techniques of crystallization and then converted to the cyclocytidine salt by the cyanovinylation process. n The cyanovinylation is carried out by reacting the aminooxazoline with cis-β-[trimethylammonium]-acrylonitrile tosylate. To obtain significant yields of the cyclocytidine salt, the reaction should be run in an inert, aprotic solvent such as the dialkylamides, for example, formamides, acetamides and other amides which are liquid at the reaction temperature. Examples of such solvents include dimethylformamide, dimethylacetamide, diethylformamide and the like. The length of time of the reaction is dependent upon the temperature. A temperature range of from about 30° to about 100°C. is generally satisfactory. A temperature range of from about 40° to about 60°C. brings about a good compromise between yield and length of the reaction. It is preferred to carry out this reaction in a flowing nitrogen atmosphere. Under these circumstances, the cyclocytidine salt is recovered as a white crystalline material. If an inert, mobile atmosphere such as nitrogen is not employed, the cyclocytidine salt is recovered as a yellow crystalline material. Analyses indicate these materials are the same. Although the reason for the observed color difference is not clear, it is believed that trimethylamine provides color to the crystals. If nitrogen is passed through the reaction vessel, the trimethylamine is driven off and white crystalline material is isolated. n As in the Orgel and Sanchez patent, previously cited, the cyclocytidine salt is readily converted to cytosine arabinoside by contacting with a dilute base such as sodium hydroxide or aqueous ammonia at room temperature or a slightly elevated temperature, for example, from 25° to about 75°C. This results in an essentially quantative yield of cytosine arabinoside and side product tosic acid. These are readily separated on a strong acid resin such as a macroreticular resin, Dowex MSC-1. The cytosine arabinoside is then further purified in a conventional manner. n The cis-β-[trimethylammonium]-acrylonitrile tosylate is prepared as follows: Isoxazole is selectively converted to the anion of cis-1-cyano-2-hydroxyethylene by contacting in an inert, aprotic solvent isoxazole with a base of strength greater than or equal to that of sodium methoxide at a temperature of less than or equal to about -40°C. As previously stated, the temperature of the isoxazole at the time of addition is critical. For example, if the isoxazole enters the reaction vessel at ambient temperature, the temperature in the vessel should be less than or equal to -40°C. However, if the isoxazole is cooled to -20°C. prior to entrance into the reaction vessel, the reaction temperature may be maintained at less than or equal to -20°C. Various combinations of isoxazole precooling and reaction vessel temperature maintenance are available for the selective production of the cis anion. n The inert organic solvents are liquid at the reaction temperature. Examples of inert organic solvents are the ethers of two to eight carbon atoms, inclusive, and cyclic ethers of four to eight carbon atoms, inclusive. Examples of such solvents include diethyl ether, dipropyl ether, dimethylformamide, diethylacetamide and the like. Additional solvents which are appropriate include 1,2-dimethoxyethane and tetrahydrofuran. n Examples of bases of appropriate strength are t-butoxide, t-amyloxide, isopropoxide, methoxide, ethoxide, and the like. Generally the cation is a metal such as sodium, potassium, lithium, etc. A preferred base solvent system is potassium tert-butoxide in tetrahydrofuran. n The temperature may be as low as is consonant with a satisfactory reaction rate. Reaction temperatures significantly above -40°C., assuming essentially no precooling of isoxazole, should be avoided since trans isomer production occurs to an undesirable extent. n The 1-cyano-2-hydroxyethylene anion is converted to a tosylate salt by standard reagents such as reaction with tosyl halide or tosyl anhydride. In order to maintain high yields, the temperature of the reaction should initially be maintained at a level less than or equal to the temperature used for the production of the cis anion. No additional solvent is necessary although a solvent in which the salt of 1-cyano-2-hydroxyethylene is soluble may be added. An example of such a solvent is acetonitrile. The by-products of the reaction are separated by extraction of the cis-β-tosyloxyacrylonitrile with an organic solvent such as ethyl acetate, toluene or benzene combined with aqueous base. n After purification, the cis-β-tosyloxyacrylonitrile prepared above is now reacted with trimethylamine in a stereospecific reaction resulting in retention, thereby forming the cis-β-[trimethylammonium]acrylonitrile tosylate. The reaction temperature is generally from about +5° to about 50°C. The reaction can be carried out in the solvent employed in the previous extraction step for separating the by-products from the cis-β-tosyloxyacrylonitrile.

专利号:US-12054512-B2
优先权日:2017-11-10
标 题 :Sting modulator compounds, and methods of making and using
发明人：VYSKOCIL STEPAN; CIAVARRI JEFFREY; CULLIS COURTNEY; ENGLAND DYLAN BRADLEY; GOULD ALEXANDRA E; GREENSPAN PAUL; HU YONGBO; LANGSTON STEVEN; LI GANG; MIZUTANI HIROTAKE; OKANIWA MASANORI
权利人:TAKEDA PHARMACEUTICALS CO
摘要:The present disclosure provides STING modulators/agonists, and methods of synthesis and methods for using for the prophylaxis or treatment of cancer and other STING-related diseases.The present disclosure relates to a compound represented by the Formula (I):wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.

专利号:RU-2129788-C1
优先权日:1995-01-20
标题:Method of suppression of phytopathogen fungi, derivative of benzophenone, a method of protection of plants from damage caused by phytopathogen fungus, a fungicide composition, methods of synthesis of benzophenones

专利号:RU-2041210-C1
优先权日:1989-11-01
标题:Method of synthesis of imidazo-(4,5-b)-quinolinylhydroxyalkanoic acid amides or their pharmaceutically used salts

专利号:SU-1500644-A1
优先权日:1987-12-18
标题 :METHYL 5-0-BENZYL-2-O-BENZOIL-ZFTOR-W-DEOXY / - AND p-B-RIBOFURANOSIDES AS SEMI-PRODUCTS IN THE SYNTHESIS OF BIOLOGICALLY ACTIVE 3 * -Fluoro-3 '-ZEOXYRIBROUS